A. Kwiatkowska et al. / European Journal of Medicinal Chemistry 44 (2009) 2862–2867
2867
[11] M. Mohamad, Horm. Res. 59 (2003) 42–54.
[12] V. Du Vigneaud, D.T. Gish, P.G. Katsoynnis, J. Am. Chem. Soc. 76 (1954)
4751–4752.
[13] K.E. Andersson, B. Arne, Acta Med. Scand. 192 (1972) 21–27.
[14] M. Manning, W.H. Sawyer, J. Lab. Clin. Med. 114 (1989) 617–632.
[15] M. Akerlund, P. Stromberg, A. Hauksson, L.F. Andersen, J. Lyndrup, P. Melin, Br.
J. Obstet. Gynaecol. 94 (1987) 1040–1045.
[16] M. Manning, S. Stoev, B. Chini, T. Durroux, B. Mouillac, G. Guillon, Prog. Brain.
Res. 170 (2008) 473–512.
[17] S.B. Paranjape, M. Thibonnier, Expert. Opin. Investig. Drugs 10 (2001)
825–834.
[18] A. Tahara, M. Saito, T. Sugimoto, Y. Tomura, K. Wada, T. Kusayama, J. Tsukada,
N. Ishii, T. Yatsu, W. Uchida, A. Tanaka, Naunyn-Schmiedebergs Arch. Phar-
macol. 357 (1998) 63–69.
In general, the presence of
with the
activity of the peptides and in the case of pressor activity it triggers
a weak vasopressin V1a antagonism.
D
-Dip at position 2, in comparison
L
-enantiomer, more distinctly enhances antidiuretic
On the basic of these results, we are undertaking further
investigations on our Dip2 and -Dip2 modified AVP analogues to
D
determine binding affinity to V1a, V1b, V2 and OT receptors. Parallely
we are performing the structural analysis and molecular modeling
of the peptides that may help to reveal processes underlying these
interesting findings.
[19] G. Griebel, J. Simiand, C. Serradeil-Le Gal, J. Wagnon, M. Pascal, B. Scatton,
J.P. Maffrand, P. Soubrie, Proc. Natl. Acad. Sci. USA 99 (2002) 6370–6375.
[20] M. Manning, W.H. Sawyer, J. Receptor Res. 13 (1993) 195–214.
6. Conclusion
ˇ
ˇ
[21] M. Lebl, K. Jost, F. Brtnik, in: K. Jost, M. Lebl, F. Brtnik (Eds.), Tables of Analogs
in Handbook of Neurohypophyseal Hormone Analogs, vol. II, CRC Press Inc.,
Boca Raton, FL, 1987, pp. 127–267 Part 2.
In summary, our studies have shown once more that the
modification of position 2 which changes conformation of the N-
terminal part of the analogue has a dramatic impact on the phar-
macological profile of the compound (in this case it resulted in
a high and prolonged V2 agonistic activity). This finding supports
our previous results showing that single substitution with some
bulky residues may result in quite potent antagonists of OT
receptors [44]. Such substitution is clearly disadvantageous when
applied to antagonists of V1a receptors, as has been documented in
our previous paper [25]. It should be emphasized that four of the
[22] I. Derdowska, A. Prahl, W. Kowalczyk, M. Janecki, S. Melhem, H.I. Trzeciak,
B. Lammek, Eur. J. Med. Chem. 40 (2005) 63–68.
[23] B. Lammek, M. Czaja, I. Derdowska, P. Rekowski, H.I. Trzeciak, P. Sikora,
W. Szkrobka, R. Stojko, G. Kupryszewski, J. Pept. Res. 49 (1997) 216–286.
[24] B. Jastrze˛bska, I. Derdowska, W. Kowalczyk, A. Machova´, J. Slaninova´,
B. Lammek, J. Pept. Res. 62 (2003) 70–77.
[25] W. Kowalczyk, A. Prahl, I. Derdowska, O. Dawidowska, J. Slaninova´, B. Lammek,
J. Med. Chem. 47 (2004) 6020–6024.
[26] W. Kowalczyk, A. Prahl, O. Dawidowska, I. Derdowska, D. Sobolweski,
B. Hartrodt, K. Neubert, J. Slaninova´, B. Lammek, J. Pept. Sci. 11 (2005)
584–588.
´
new peptides ([Mpa1,
D
-Dip2]AVP, [Mpa1,
D
-Dip2,Val4]AVP, [Mpa1,
[27] W. Kowalczyk, A. Prahl, I. Derdowska, D. Sobolewski, J. Olejnik, J. Zabrocki,
D
-Dip2, -Arg8]VP, [Mpa1,
D
D
-Dip2,Val4, -Arg8]VP) are exceptionally
D
´
´
L. Borovickova, J. Slaninova, B. Lammek, J. Med. Chem. 49 (2006) 2016–2021.
[28] M. Bodanszky, A. Bodanszky, The Practice of Peptide Synthesis, Springer-
Verlag, Berlin, 1984, p. 83.
potent antidiuretic agonists with significantly prolonged activities,
which makes them good candidates for studying the physiological
role of AVP and potential therapeutic agents.
[29] P. Rekowski, B. Lammek, Pol. J. Chem. 61 (1987) 907–911.
[30] M. Schno¨lzer, P. Alewood, A. Jones, D. Alewood, S. Kent, Int. J. Pept. Protein Res.
40 (1992) 180–193.
[31] E. Kaiser, R.I. Colescott, C.D. Bossinger, P. Cook, Anal. Biochem. 34 (1970)
595–598.
Acknowledgement
[32] T.C. Christensen, in: E. Gross, J. Meienhofer (Eds.), Peptides – Structure and
Biological Function, Pierce Chem. Corp., Rockford, USA, 1979, p. 385.
[33] J.M. Stewart, Solid Phase Peptide Synthesis, Pierce Chem. Corp., Rockford, USA,
1984, p. 87.
[34] G. Flouret, S. Terada, T. Kato, R. Gualtieri, A. Lipkowski, Int. J. Pept. Protein. Res.
13 (1979) 137–141.
Partial funding for this work was provided by grant 0230/B/H03/
2008/35 and by research project no. Z4055905 of the Academy of
Sciences of the Czech Republic.
[35] P.A. Holton, Br. J. Pharmacol. 3 (1948) 328–334.
[36] J. Rudinger, I. Krejci, Experientia 18 (1962) 585–588.
[37] J. Dekanski, Br. J. Pharmacol. 7 (1952) 567–572.
References
´
ˇ
´
[38] J. Slaninova, in: K. Jost, M. Lebl, F. Brtnık (Eds.), Handbook of Neurohypo-
physeal Hormone analogs, vol. I, CRC Press Inc., Boca Raton, Florida, 1987, pp.
83–107 Part 2.
[1] C. Barberis, B. Mouillac, T. Durroux, J. Endocrinol. 156 (1998) 223–229.
[2] C. Barberis, D. Morin, T. Durroux, B. Mouillac, G. Guillon, R. Seyer, M. Hibert,
E. Tribollet, M. Manning, Drug News Perspect. 12 (1999) 279–292.
[3] S. Jard, Kidney Int. 34 (1988) 38–42.
[4] G. Gimpl, F. Fahrenholz, Physiol. Rev. 81 (2001) 629–683.
[5] S. Jard, Vasopressin receptors. A historical survey, in: H.H. Zingg, C.W. Bourque,
D.G. Bichet (Eds.), Advances in Experimental Medicine and Biology, Plenum
Press, New York, 1998, pp. 1–13.
[6] G. Guillon, M. Trueba, D. Joubert, E. Grazzini, L. Chouinard, M. Cote, M.D. Payet,
O. Manzoni, C. Barberis, M. Robert, N. Gallot-Payet, Endocrinology 136 (1995)
1285–1295.
[7] Z.Y. Gao, M. Gerard, J.C. Henquin, Regul. Pept. 38 (1992) 89–98.
[8] P.T. Manning, D. Schwartz, N.C. Katsuble, S.W. Holmberg, P. Needleman,
Science 229 (1985) 395–397.
[39] H.J. Burn, D.J. Finney, L.G. Goodwin, Biological Standardization, second ed.
Oxford University Press, London, 1950, 187.
[40] I. Vavra, A. Machova, I. Krejcı,
´
´
ˇ´ J. Pharmacol. Exp. Ther. 188 (1974) 241–247.
ˇ
´
[41] W. Kowalczyk, D. Sobolewski, A. Prahl, I. Derdowska, L. Borovickova,
´
J. Slaninova, B. Lammek, J. Med. Chem. 50 (2007) 2926–2929.
[42] M. Manning, K. Ban´ kowski, W.H. Sawyer, Vasopressin, Plenum Press, New
York, 1987, pp 335–368.
[43] M. Manning, W.H. Sawyer, in: R.W. Schrier (Ed.), Vasopressin, Raven Press,
New York, 1985, pp. 131–144.
[44] M. Sobocinska, E. qempica, E. Konieczna, I. Derdowska, B. Lammek, S. Melhem,
´
W. Kozik, J. Janecka, M. Janecki, H.I. Trzeciak, J. Pharm. Pharmacol. 52 (2000)
1105–1112.
[9] F.C. Bartter, W.B. Schwartz, Am. J. Med. 42 (1967) 790–806.
[10] L. Kovasc, G.L. Robertson, Endocrinol. Metab. Clin. North Am. 21 (1992)
859–875.
[45] J. Skopkova, P. Hrbas, J. Slaninova, T. Barth, Collect. Czech Chem. Commun. 46
(1981) 1850–1855.